Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumexa Imaging HoldingsLMRI +3.42%9 EV-to-EBITDA is 39.77 as of Aug. 13, 2026, which is 77% above its 10-year median of 22.52. GuruFocus rates LMRI with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 514 Medical Devices & Instruments companies, Lumexa Imaging Holdings ranks worse than 83.66% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lumexa Imaging Holdings's enterprise value is $2,079.8 Mil.
Lumexa Imaging Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $52.3 Mil. Therefore, Lumexa Imaging Holdings's EV-to-EBITDA for today is 39.77.
The historical rank and industry rank for Lumexa Imaging Holdings's EV-to-EBITDA or its related term are showing as below:
LMRI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 17.56 Med: 22.52 Max: 45.6
Current: 39.77
During the past 3 years, the highest EV-to-EBITDA of Lumexa Imaging Holdings was 45.60. The lowest was 17.56. And the median was 22.52.
LMRI's EV-to-EBITDA is ranked worse than 83.66% of 514
companies
in the Medical Devices & Instruments industry
Industry Median: 14.825
vs LMRI: 39.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lumexa Imaging Holdings's PE Ratio (TTM) for today is calculated as:
Lumexa Imaging Holdings's share price for today is $12.11.
Lumexa Imaging Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lumexa Imaging Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumexa Imaging Holdings EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumexa Imaging Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lumexa Imaging Holdings's EV-to-EBITDA falls into.
Lumexa Imaging Holdings's current Enterprise Value is $2,079.8 Mil.
Lumexa Imaging Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumexa Imaging Holdings (LMRI) has a EV-to-EBITDA of 39.77 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lumexa Imaging Holdings. This is 77% above median its historical median of 22.52. Over the past decade, Lumexa Imaging Holdings' EV-to-EBITDA has ranged from 17.56 to 45.60. According to the industry distribution chart, Lumexa Imaging Holdings ranks #430 out of 514 companies in the Medical Devices & Instruments industry, placing it in the top 83.7%.
Is Lumexa Imaging Holdings' EV-to-EBITDA too high?
Lumexa Imaging Holdings' current EV-to-EBITDA of 39.77 is 77% above median its 10-year median of 22.52. Over the past 10 years, this metric has ranged from a low of 17.56 to a high of 45.60. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.83. Lumexa Imaging Holdings' value of 39.77 is 168.3% above this industry median. Based on the distribution chart, Lumexa Imaging Holdings ranks #430 out of 514 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lumexa Imaging Holdings has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Lumexa Imaging Holdings' EV-to-EBITDA compare to QDEL and PRCT?
According to the Medical Devices & Instruments industry distribution chart, Lumexa Imaging Holdings ranks #430 out of 514 companies for EV-to-EBITDA. This places Lumexa Imaging Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 14.83. Lumexa Imaging Holdings' value of 39.77 is 168.3% above this benchmark. Historically, Lumexa Imaging Holdings' own EV-to-EBITDA has ranged from 17.56 to 45.60 over the past decade. While the company's 10-year median is 22.52 vs. the industry median of 14.83, Lumexa Imaging Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.83, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumexa Imaging Holdings's current EV-to-EBITDA of 39.77 is 168.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lumexa Imaging Holdings. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumexa Imaging Holdings's current EV-to-EBITDA is 39.77, which is 77% above median its own 10-year median of 22.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumexa Imaging Holdings stock overvalued right now?
Lumexa Imaging Holdings (LMRI) has a current EV-to-EBITDA of 39.77. The current EV-to-EBITDA is 39.77, which is 77% above median its 10-year median of 22.52 and 168.3% above the Medical Devices & Instruments industry median of 14.83. Lumexa Imaging Holdings' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lumexa Imaging Holdings (LMRI), the current EV-to-EBITDA is 39.77 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.
9GF Score
Get the complete analysis for LMRI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMRI has been successfully added to your 
